Jupiter Neurosciences Inc Dossier - Source-backed chat

Jupiter Neurosciences Inc

JUNSNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.81

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.55Price as of 2 Oct 2026

Data confidenceNot applicable

Market Cap $3.4M

Enterprise Value $4.9M

Shares Outstanding 1.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company utilizing its proprietary, enhanced bioavailability resveratrol formulation (JOTROL) to target neuroinflammation and central nervous system (CNS) disorders. The company operates a dual-path business model, combining high-risk drug development with a near-term consumer longevity supplement line (Nugevia). While the initiation of patient enrollment in the Phase IIa RESET trial for Parkinson's disease and the proposed licensing of PharmAla's ALA-002 program represent significant pipeline milestones, the company faces severe financial distress. With a going-concern warning, heavy cash burn, substantial debt from convertible notes, and pending Nasdaq delisting threats due to non-compliance with minimum bid price and MVLS rules, the stock remains highly speculative. A neutral view is warranted as investors await the outcome of the upcoming July 2026 shareholder vote on a discretionary reverse stock split and initial clinical readouts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Jupiter fails to regain compliance with Nasdaq listing standards by the August 25, 2026 deadline, leading to delisting to the OTC markets, which severely impairs stock liquidity. The Phase IIa RESET trial experiences severe enrollment delays or safety issues, and the non-binding term sheet with PharmAla falls through. The company's cash runway is exhausted, forcing highly dilutive share issuances or restructuring under its heavy convertible debt burden.

Base CaseCentral scenario

The company successfully executes a reverse stock split (proposed between 1:10 and 1:100) following the July 22, 2026 annual meeting, thereby regaining compliance with Nasdaq's $1.00 minimum bid price rule. Patient enrollment for the Phase IIa RESET trial in Parkinson's disease progresses steadily, and the licensing agreement for PharmAla's ALA-002 program is finalized. Nugevia supplement sales provide modest, high-margin cash inflows, but the company remains highly dependent on dilutive equity financing under its SEPA facility to sustain operations.

Bull CaseUpside scenario

Jupiter's bull case centers on its dual-engine model: the clinical validation of JOTROL™ in the Phase 2a RESET trial for Parkinson's disease (expected H1 2027) and the rapid commercialization of the newly licensed, patented MDMA candidate ALA-002 in the multi-billion-dollar U.S. psychedelic-assisted therapy market, supported by its direct-to-consumer longevity line Nugevia™.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary JOTROL platform solves the historical bioavailability and gastrointestinal toxicity issues of resveratrol, enabling therapeutic dosing.
Active Phase IIa RESET clinical trial in Parkinson's disease targeting a multi-billion dollar market with no current disease-modifying therapies.
Dual-path commercial model with the Nugevia consumer longevity line generating early, high-margin revenues to complement the clinical pipeline.
Strategic expansion into the psychedelic space via a term sheet to acquire exclusive U.S. licensing rights to PharmAla's next-generation MDMA candidate (ALA-002).

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
Pending Nasdaq delisting risk with deadlines on August 25, 2026, for both the $1.00 minimum bid price and $35 million MVLS requirements.
High financial leverage and dilution risk from $5.5 million in outstanding principal of convertible promissory notes and the Yorkville SEPA facility.
Clinical-stage risk, where failure or delay in the Phase IIa RESET trial would severely damage the company's valuation and viability.

Thesis Invalidation Triggers

Delisting of JUNS common stock from the Nasdaq Capital Market to the OTC Bulletin Board.
Failure of the Board to secure stockholder approval for the discretionary reverse stock split at the July 22, 2026 annual meeting.
Termination or failure to finalize the definitive licensing agreement for PharmAla's ALA-002 program.
Inability to secure additional capital, leading to a suspension of the Phase IIa RESET clinical trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.